首页> 美国卫生研究院文献>Molecular Therapy. Nucleic Acids >siRNA-mediated Allele-specific Silencing of a COL6A3 Mutation in a Cellular Model of Dominant Ullrich Muscular Dystrophy
【2h】

siRNA-mediated Allele-specific Silencing of a COL6A3 Mutation in a Cellular Model of Dominant Ullrich Muscular Dystrophy

机译:siRNA介导的主要Ullrich肌营养不良症细胞模型中COL6A3突变的等位基因特异性沉默。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Congenital muscular dystrophy type Ullrich (UCMD) is a severe disorder of early childhood onset for which currently there is no effective treatment. UCMD commonly is caused by dominant-negative mutations in the genes coding for collagen type VI, a major microfibrillar component of the extracellular matrix surrounding the muscle fibers. To explore RNA interference (RNAi) as a potential therapy for UCMD, we designed a series of small interfering RNA (siRNA) oligos that specifically target the most common mutations resulting in skipping of exon 16 in the COL6A3 gene and tested them in UCMD-derived dermal fibroblasts. Transcript analysis by semiquantitative and quantitative reverse transcriptase PCR showed that two of these siRNAs were the most allele-specific, i.e., they efficiently knocked down the expression from the mutant allele, without affecting the normal allele. In HEK293T cells, these siRNAs selectively suppressed protein expression from a reporter construct carrying the mutation, with no or minimal suppression of the wild-type (WT) construct, suggesting that collagen VI protein levels are as also reduced in an allele-specific manner. Furthermore, we found that treating UCMD fibroblasts with these siRNAs considerably improved the quantity and quality of the collagen VI matrix, as assessed by confocal microscopy. Our current study establishes RNAi as a promising molecular approach for treating dominant COL6-related dystrophies.
机译:先天性肌营养不良型乌尔里希(UCMD)是一种严重的幼儿期疾病,目前尚无有效的治疗方法。 UCMD通常是由编码VI型胶原(肌肉纤维周围细胞外基质的主要微原纤维成分)的基因中的显性负突变引起的。为了探索RNA干扰(RNAi)作为UCMD的潜在疗法,我们设计了一系列小干扰RNA(siRNA)寡核苷酸,这些寡核苷酸专门针对最常见的突变,从而导致COL6A3基因中外显子16的跳跃,并在UCMD来源中进行了测试真皮成纤维细胞。通过半定量和定量逆转录酶PCR进行的转录本分析表明,这些siRNA中的两个是等位基因特异性最高的,即它们有效地敲除了突变体等位基因的表达,而不会影响正常等位基因。在HEK293T细胞中,这些siRNA选择性抑制携带突变的报告基因构建体的蛋白表达,而对野生型(WT)构建体没有抑制或抑制作用很小,表明胶原VI蛋白水平也以等位基因特异性方式降低。此外,我们发现,通过共聚焦显微镜评估,用这些siRNA处理UCMD成纤维细胞可显着提高胶原VI基质的数量和质量。我们当前的研究将RNAi确立为治疗主要COL6相关营养不良的有前途的分子方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号